BioCentury | Nov 30, 2020
Management Tracks

New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

Ascletis is looking to Takeda veteran Melissa Palmer to move its pipeline of in-licensed and homegrown NASH programs forward. Ascletis Pharma Inc. (HKEX:1672) announced Monday that Palmer, the former head of liver disease clinical development at...
BioCentury | Nov 25, 2020
Emerging Company Profile

Building Resilience into U.S. biomanufacturing

...Vice Chairman Patrick Yang was EVP at CAR...
BioCentury | Nov 24, 2020
Product Development

ASH preview & long shot drug pricing rules: a BioCentury podcast

...authorization. Associate Editor Karen Tkach Tuzman says the data from ASH are mixed on whether allogenic CAR...
BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

...How Catamaran is designing off-the-shelf CAR NK cells to broaden the reach of cell therapies By...
...debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR...
...Rubius Therapeutics Inc. (NASDAQ:RUBY); and CMO Chris Carpenter, who was Rubius’ CMO.The company is generating CAR...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

...cells to cancer cells while avoiding the complex manufacturing processes of CAR Ts, but like CAR...
...the same: finding targets selectively expressed on solid tumor cells. The target space for standard CAR...
BioCentury | Nov 21, 2020
Regulation

Nov. 20 Quick Takes: Approvals in Europe for Alnylam, Alexion therapies; plus FDA priority review for ADC, Sanofi and more

...avalglucosidase alfa, an enzyme replacement therapy, to treat Pompe disease.FDA lifts clinical hold on Cellectis’ CAR...
...UCARTCS1A to treat patients with multiple myeloma. The agency placed the hold on the allogeneic CAR...
BioCentury | Nov 21, 2020
Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

...by offering patients the option of a car...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

...vivo gene correction application of its ARCUS platform, which has lagged its clinical pipeline of CAR...
...for allogeneic CAR T therapies, in vivo gene correction, and crop plants. Three of its CAR...
BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

...platform could allow the newly launched start-up to create off-the-shelf cell therapy cocktails that expand CAR...
...be activated and controlled by exogenously administered small molecules. The payload system, which Umoja calls RACR/CAR...
...Jensen, who had been working on the project alongside Low. He was a co-founder of CAR...
BioCentury | Nov 19, 2020
Management Tracks

CStone’s Yeh joins Abbisko as CFO; plus moves at Ziopharm, Permira, Imara, Inivata, Topas and Arch

...joined Ziopharm Oncology Inc. (NASDAQ:ZIOP) as CMO. Baffa was CMO and head of R&D at CAR...
Items per page:
1 - 10 of 1957